RE:RE:RE:RE:acu193 question
Was there a mention of Acumen in a prior corporate update? I know ACU193 appears in a paper by Cashman & Plotkin, but it wouldn't fit well in a table comparing P2-3 drugs to demonstrate the need for oligomer selectivity, it needs to fail first.
I like the direction of evololution of this document.
I'd like to see a summary of P1 level competion framed in the context of next generation drugs in developement, and ACU193 would certainly fit there. I think that can be done without casting shade and doing so would help potential investors' DD, as well as demonstrating managerial confidence and competence. Seems like a no brainer when the facts are on your side.